SAB Bio completes Phase 1 healthy-volunteer enrollment; SAB-142 shows no serum sickness at 2.5 mg/kg

SAB Biotherapeutics, Inc.

Phase 1 trial of SAB-142 for type 1 diabetes completed all planned healthy-volunteer cohorts; no serum sickness observed at target 2.5 mg/kg dose.
Company now enrolling type 1 diabetes patients in the last cohort of the Phase 1 study.
Topline Phase 1 data readout expected by end of 2024.
SAB-142 is a first-in-class human anti-thymocyte immunoglobulin with differentiated safety profile compared to rabbit ATG.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.